• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

我如何治疗慢性髓性白血病患者的肥胖症及肥胖相关手术：欧洲白血病网项目的一项成果

How I treat obesity and obesity related surgery in patients with chronic myeloid leukemia: An outcome of an ELN project.

作者信息

Yassin Mohamed A, Kassem Nancy, Ghassoub Rola

机构信息

Hematology Section Medical Oncology National Center for Cancer care and Research HMC Doha Qatar.

Department of Pharmacy National center for cancer care and Research HMC Doha Qatar.

出版信息

Clin Case Rep. 2021 Jan 8;9(3):1228-1234. doi: 10.1002/ccr3.3738. eCollection 2021 Mar.

DOI:10.1002/ccr3.3738
PMID:33768817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7981640/
Abstract

Obesity may affect treatment outcome in CML patients, therefore the treatment of this cohort of patients need careful monitoring, TKIs dose adjustment may be required for certain patients. Further studies are needed to determine the proper TKIs doses.

摘要

肥胖可能会影响慢性粒细胞白血病（CML）患者的治疗结果，因此对这组患者的治疗需要仔细监测，某些患者可能需要调整酪氨酸激酶抑制剂（TKIs）的剂量。需要进一步研究以确定合适的TKIs剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/73e0e90461a5/CCR3-9-1228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/bff8d755d780/CCR3-9-1228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/f685c97ca6ce/CCR3-9-1228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/73e0e90461a5/CCR3-9-1228-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/bff8d755d780/CCR3-9-1228-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/f685c97ca6ce/CCR3-9-1228-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da2b/7981640/73e0e90461a5/CCR3-9-1228-g004.jpg

相似文献

1
How I treat obesity and obesity related surgery in patients with chronic myeloid leukemia: An outcome of an ELN project.我如何治疗慢性髓性白血病患者的肥胖症及肥胖相关手术：欧洲白血病网项目的一项成果
Clin Case Rep. 2021 Jan 8;9(3):1228-1234. doi: 10.1002/ccr3.3738. eCollection 2021 Mar.
2
Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study.与坚持使用长期酪氨酸激酶抑制剂控制慢性髓性白血病相关的药物治疗问题：一项定性研究
Patient Prefer Adherence. 2017 Jun 6;11:1027-1034. doi: 10.2147/PPA.S132894. eCollection 2017.
3
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.酪氨酸激酶抑制剂长期治疗慢性髓性白血病的疗效和心血管不良事件：长崎 CML 研究组报告。
Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22.
4
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.根据欧洲白血病网标准，相当一部分慢性髓性白血病患者反应欠佳，但未经治疗调整却预后良好。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30.
5
NCCN and ELN: What do the guidelines tell us?美国国立综合癌症网络（NCCN）和欧洲白血病网络（ELN）：这些指南告诉了我们什么？
Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. doi: 10.1016/j.beha.2016.10.016. Epub 2016 Oct 20.
6
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.低剂量酪氨酸激酶抑制剂在治疗停止前使用不会损害慢性髓性白血病患者的无治疗缓解：一项回顾性研究的结果。
Cancer. 2020 Aug 1;126(15):3438-3447. doi: 10.1002/cncr.32940. Epub 2020 May 27.
7
Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.基于欧洲白血病网络 2013 年推荐的慢性髓细胞白血病治疗不足和过度治疗的当前关注点。
Expert Opin Pharmacother. 2013 Oct;14(15):2005-10. doi: 10.1517/14656566.2013.833185. Epub 2013 Aug 28.
8
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.酪氨酸激酶抑制剂与慢性髓性白血病患者血管不良事件：基于人群、倾向评分匹配队列研究。
Oncologist. 2021 Nov;26(11):974-982. doi: 10.1002/onco.13944. Epub 2021 Sep 12.
9
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.慢性髓性白血病、酪氨酸激酶抑制剂与心血管系统。
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5493-5506. doi: 10.26355/eurrev_202306_32786.
10
Current perspectives for the treatment of chronic myeloid leukemia.慢性髓性白血病治疗的现状。
Turk J Med Sci. 2019 Feb 11;49(1):1-10. doi: 10.3906/sag-1810-81.

引用本文的文献

1
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review.深入探讨慢性髓性白血病中肥胖的手术和药理学考量：一项叙述性综述。
Front Oncol. 2025 Jul 4;15:1616883. doi: 10.3389/fonc.2025.1616883. eCollection 2025.
2
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials.肿瘤学中的精准医学：利用虚拟临床试验确定肥胖癌症患者群体的伊马替尼给药剂量。
CPT Pharmacometrics Syst Pharmacol. 2025 Jun;14(6):1050-1064. doi: 10.1002/psp4.70018. Epub 2025 Mar 27.
3
Chronic Myeloid Leukemia in Adolescents and Young Adults: Clinicopathological Variables and Outcomes.

本文引用的文献

1
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.目标：对 33 个国家慢性髓性白血病的真实世界管理进行调查。
Br J Haematol. 2020 Sep;190(6):869-876. doi: 10.1111/bjh.16599. Epub 2020 Mar 30.
2
Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.肥胖与药物药理学：肥胖对药代动力学和药效学参数影响的综述
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):275-285. doi: 10.1080/17425255.2018.1440287. Epub 2018 Feb 15.
3
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.
青少年及青年慢性髓系白血病：临床病理变量与预后
Oncology. 2024;102(12):1018-1028. doi: 10.1159/000539982. Epub 2024 Jul 16.
4
Radioactive Iodine-Induced Chronic Myeloid Leukemia in a Patient With Graves' Disease: A Case Report.放射性碘诱发的格雷夫斯病患者慢性髓性白血病：一例报告
Cureus. 2023 Feb 22;15(2):e35295. doi: 10.7759/cureus.35295. eCollection 2023 Feb.
5
Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97).焦虑、年龄和动机对骨髓增殖性肿瘤患者的体力活动有影响——来自东德血液学和肿瘤学研究小组（OSHO #97）的多中心调查。
Front Oncol. 2023 Jan 4;12:1056786. doi: 10.3389/fonc.2022.1056786. eCollection 2022.
6
Patient with clinical celiac disease mimicking triple-negative essential thrombocythemia.患有临床乳糜泻且表现类似三阴性原发性血小板增多症的患者。
Clin Case Rep. 2022 Apr 7;10(4):e05197. doi: 10.1002/ccr3.5197. eCollection 2022 Apr.
7
Avascular necrosis in patients with chronic myeloid leukemia: A systematic review.慢性髓性白血病患者的无血管性坏死：一项系统综述。
Acta Biomed. 2022 Mar 14;93(1):e2022017. doi: 10.23750/abm.v93i1.12270.
8
Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review.重症肌无力与骨髓增生性肿瘤——仅仅是关联还是副肿瘤神经系统综合征：一篇迷你综述。
Acta Biomed. 2022 Jan 19;92(6):e2021437. doi: 10.23750/abm.v92i6.12180.
9
Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.原发性骨髓纤维化患者的溶骨性骨病变：系统评价。
Acta Biomed. 2022 Jan 19;92(6):e2021478. doi: 10.23750/abm.v92i6.12350.
10
Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.达沙替尼一线治疗慢性髓性白血病（慢性期）患者致直肠 spared 性结肠炎：病例报告
Case Rep Oncol. 2021 Oct 18;14(3):1441-1446. doi: 10.1159/000516794. eCollection 2021 Sep-Dec.
体重指数对接受第二代酪氨酸激酶抑制剂一线治疗的慢性髓性白血病患者的分子反应率没有影响。
Br J Haematol. 2018 Aug;182(3):427-429. doi: 10.1111/bjh.14783. Epub 2017 Jul 5.
4
Health Effects of Overweight and Obesity in 195 Countries over 25 Years.25年间195个国家超重和肥胖对健康的影响
N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362. Epub 2017 Jun 12.
5
Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.慢性髓性白血病患者伊马替尼、尼洛替尼和达沙替尼的治疗药物监测
Biol Pharm Bull. 2015;38(5):645-54. doi: 10.1248/bpb.b15-00103.
6
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.胃肠道切除术对胃肠间质瘤患者舒尼替尼暴露量的影响。
BMC Cancer. 2014 Aug 8;14:575. doi: 10.1186/1471-2407-14-575.
7
The use of drugs in patients who have undergone bariatric surgery.在接受减肥手术的患者中使用药物。
Int J Gen Med. 2014 May 14;7:219-24. doi: 10.2147/IJGM.S55332. eCollection 2014.
8
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
9
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.在接受伊马替尼治疗的慢性髓性白血病患者中，基线时 BMI 增加与延迟细胞遗传学和主要分子反应相关。
Cancer Lett. 2013 Jun 1;333(1):32-5. doi: 10.1016/j.canlet.2012.12.018. Epub 2013 Jan 3.
10
The effects of gastric bypass surgery on drug absorption and pharmacokinetics.胃旁路手术对药物吸收和药代动力学的影响。
Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1505-19. doi: 10.1517/17425255.2012.722757. Epub 2012 Sep 24.